GlaxoSmithKline Pharmaceuticals — 360° view

GlaxoSmithKline Pharmaceuticals, a company in the Pharmaceuticals industry, reported revenue of ₹1,184 crore and net profit of ₹336 crore for the September 2026 quarter.

GlaxoSmithKline Pharmaceuticals (NSE: GLAXO) closed at ₹2,727.60 on 20 Nov 2026, up 8.7% over the past year. Its market capitalisation is ₹46,207 crore and it trades at 40.8 times earnings.

Share price
₹2,727.60 (20 Nov 2026)
Market cap
₹46,207 Cr (20 Nov 2026)
P/E
40.77 (20 Nov 2026)
Revenue
₹1,184 Cr (September 2026 quarter)
Net profit
₹336 Cr (September 2026 quarter)
ROCE
61.4% (FY26)
ROE
45.6% (FY26)
Book value
₹111 (FY26)
Dividend yield
2.09% (last 12 months to 20 Nov 2026)
52-week high / low
₹3,120.70 / ₹2,088.10 (20 Nov 2026)
1-year return
8.7% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: GLAXO

GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.(Source : Company Web-site)

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.